This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Transthyretin cardiac amyloidosis (ATTR-CA) is the most common type of amyloid cardiomyopathy which frequently presents with cardiac arrythmias. However, the impact of SGLT2i on cardiovascular outcomes in patients with established cardiac arrythmias and ATTR-CA has not yet been evaluated.
Patients diagnosed with reduced ejectionfraction (HFrEF) and with heart failure with mildly reduced ejectionfraction (HFmrEF) were treated with Vericiguat combined with “ARNI, BB, MRA, SGLT2i” therapy. vs. 43.1 ± 8.5%, P < 0.01), LVEDD (60.5 ± 8.1 vs. 58.2 ± 7.3 mm, mm, P < 0.01), NT-proBNP (4,567.8 ± 5,163.9
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. 12:15 p.m.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preservedejectionfraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. The effect of finerenone according to glycaemic status (i.e.
Ninerafaxstat is designed to help the heart work more efficiently by altering how the muscle uses energy, partially inhibiting the use of fatty acids as fuel and encouraging the use of glucose instead. HCM is the most common genetic heartdisease worldwide and is estimated to affect 1 in 500 people.
The risk of allcause and noncardiovascular mortality and first allcause hospitalization was higher with EF values >55% in crude but not adjusted analyses.ConclusionsAmong patients with HF with preserved EF, 21% had EF 60%.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content